Diagnosis of Recurrent C Difficile Infections

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions. Definitive diagnosis requires molecular and immunological testing of stool samples to detect toxin genes and active toxin production.

EP: 1.The Role of Testing for C Difficile in Clinical Practice

EP: 2.Utilizing Antibiotics in Treatment of C Difficile

EP: 3.Examining FMT for Patients With Recurrent C Difficile infections

EP: 4.Exploring Rebyota for Recurrent C Difficile Infections

EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections

EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections

EP: 7.Management of Recurrent C Difficile Infections in the Future

EP: 8.Key Background Information on Recurrent C. Difficile Infections

EP: 9.Importance of Early Detection of Recurrent C Difficile Infections

EP: 10.Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life

Now Viewing

EP: 11.Diagnosis of Recurrent C Difficile Infections

EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections

EP: 13.Unmet Needs With Recurrent C Difficile Infections

Video content above is prompted by the following:

• What is in your differential diagnosis when considering recurrent C difficile infections?
• How is a definitive diagnosis made?

Related Videos

Related Content

Advertisement

June 18th 2025

Twice-Yearly Lenacapavir Approval Marks Major Milestone in Prevention of HIV

Julia Bonavitacola

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 16th 2025

Methotrexate Adds No Benefit to Adalimumab in Psoriasis Treatment, Study Suggests

Pearl Steinzor

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 14th 2025

A Look at Those With Durable Responses to Epcoritamab in LBCL

Mary Caffrey

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

June 14th 2025

EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures

Christina Mattina

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.

Related Content

Advertisement

June 18th 2025

Twice-Yearly Lenacapavir Approval Marks Major Milestone in Prevention of HIV

Julia Bonavitacola

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 16th 2025

Methotrexate Adds No Benefit to Adalimumab in Psoriasis Treatment, Study Suggests

Pearl Steinzor

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 14th 2025

A Look at Those With Durable Responses to Epcoritamab in LBCL

Mary Caffrey

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

June 14th 2025

EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures

Christina Mattina

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.